دورية أكاديمية
A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS).
| العنوان: | A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS). |
|---|---|
| المؤلفون: | Dini N; Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Khoshbin AP; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Aliannejad R; Thoracic Research Center, Department of Internal Medicine, Division of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran., Bakhshandeh H; Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran., Najafizadeh K; Shahid Beheshti University of Medical Sciences, Tehran, Iran., Mehdizadeh M; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Amini S; Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. aminishahideh@gmail.com. |
| المصدر: | Trials [Trials] 2024 Apr 06; Vol. 25 (1), pp. 243. Date of Electronic Publication: 2024 Apr 06. |
| نوع المنشور: | Randomized Controlled Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : BioMed Central, 2006- |
| مواضيع طبية MeSH: | Bronchiolitis Obliterans Syndrome* , Pulmonary Disease, Chronic Obstructive*/diagnosis , Pulmonary Disease, Chronic Obstructive*/drug therapy , Hematopoietic Stem Cell Transplantation*/adverse effects, Humans ; Tiotropium Bromide/adverse effects ; Cross-Over Studies ; Iran ; Bronchodilator Agents/adverse effects ; Double-Blind Method |
| مستخلص: | Background: Despite the fundamental progress in hematopoietic stem cell transplant, this treatment is also associated with complications. Graft-versus-host disease is a possible complication of HSCT. Bronchiolitis obliterans syndrome (BOS) is the pulmonary form of this syndrome. Due to the high morbidity and mortality rate of BOS, various studies have been conducted in the field of drug therapy for this syndrome, although no standard treatment has yet been proposed. According to the hypotheses about the similarities between BOS and chronic obstructive pulmonary disease, the idea of using tiotropium bromide as a bronchodilator has been proposed. Method/design: A randomized, double-blind, placebo-controlled, and crossover clinical trial is being conducted to evaluate the efficacy of tiotropium in patients with BOS. A total of 20 patients with BOS were randomly assigned (1:1) to receive a once-daily inhaled capsule of either tiotropium bromide (KP-Tiova Rotacaps 18 mcg, Cipla, India) or placebo for 1 month. Patients will receive tiotropium bromide or placebo Revolizer added to usual standard care. Measurements will include spirometry and a 6-min walking test. Ethics/dissemination: This study was approved by the Research Ethics Committees of Imam Khomeini Hospital Complex, Tehran University of Medical Science. Recruitment started in September 2022, with 20 patients randomized. The treatment follow-up of participants with tiotropium is currently ongoing and is due to finish in April 2024. The authors will disseminate the findings in peer-reviewed publications, conferences, and seminar presentations. Trial Registration: Iranian Registry of Clinical Trial (IRCT) IRCT20200415047080N3. Registered on 2022-07-12, 1401/04/21. (© 2024. The Author(s).) |
| References: | Ditschkowski M, Elmaagacli A, Koldehoff M, Gromke T, Trenschel R, Beelen D. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight—new perspectives? Bone Marrow Transplant. 2013;48(9):1224. (PMID: 10.1038/bmt.2013.1723435515) Grønningsæter IS, Tsykunova G, Lilleeng K, Ahmed AB, Bruserud Ø, Reikvam H. Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. Expert Rev Clin Immunol. 2017;13(6):553–69. (PMID: 10.1080/1744666X.2017.127905328052713) Kaner RJ, Zappetti D, Negrin RS. Pulmonary complications after allogeneic hematopoietic cell transplantation. UpToDate [online serial] Waltham, MA: UpToDate; 2022. Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. The 2014 Clinical Trial Design Working Group report. Biol Blood Marrow Transplant. 2015;21(8):1343–59. (PMID: 10.1016/j.bbmt.2015.05.004259859214506719) Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med. 2014;370(19):1820–8. (PMID: 10.1056/NEJMra120466424806161) Soubani A, Uberti J. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J. 2007;29(5):1007–19. (PMID: 10.1183/09031936.0005280617470622) Bergeron A, Godet C, Chevret S, Lorillon G, De Latour RP, De Revel T, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant. 2013;48(6):819. (PMID: 10.1038/bmt.2012.24123208317) Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128(1):153–61. (PMID: 10.1378/chest.128.1.15316002929) Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–79. (PMID: 10.1056/NEJMra170347229281578) Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074–82. (PMID: 10.1182/blood-2009-02-202937192702602686178) Gilman AL, Schultz KR, Goldman FD, Sale GE, Krailo MD, Chen Z, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children’s Oncology Group study. Biol Blood Marrow Transplant. 2012;18(1):84–91. (PMID: 10.1016/j.bbmt.2011.05.01621689773) Flowers ME, Martin PJ. Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease. Leuk Lymphoma. 2003;44(7):1141–6. (PMID: 10.1080/104281903100007909612916865) Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48–51. (PMID: 10.1182/blood.V100.1.4812070007) Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, de LatourPeffault R, et al. Budesonide/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191(11):1242–9. (PMID: 10.1164/rccm.201410-1818OC25835160) Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25(3):490–3. (PMID: 10.1183/09031936.05.0002080415738293) Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant. 2010;29(12):1358–68. (PMID: 10.1016/j.healun.2010.05.02320619683) Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–6. (PMID: 10.1016/j.bbmt.2015.10.00926475726) Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–8. (PMID: 10.1038/leu.2015.212262288134854652) Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709–18. (PMID: 10.1182/blood-2009-02-20415619403889) Kawassaki AM, Kawano-Dourado L, Kairalla RA. Tiotropium use and pulmonary function in patients with constrictive bronchiolitis. J Bras Pneumol. 2014;40(1):86–8. (PMID: 10.1590/S1806-37132014000100014246262764075920) Verleden SE, Sacreas A, Vos R, Vanaudenaerde BM, Verleden GM. Advances in understanding bronchiolitis obliterans after lung transplantation. Chest. 2016;150(1):219–25. (PMID: 10.1016/j.chest.2016.04.01427212132) Toumpanakis D, Loverdos K, Tzouda V, Vassilakopoulou V, Litsiou E, Magkou C, Vassilakopoulos T. Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction. Int J Chron Obstruct Pulmon Dis. 2017;12:2207. (PMID: 10.2147/COPD.S137587288148495546183) Lim JU, Park S, Yoon JH, Lee SE, Cho BS, Kim YJ, Lee S, Kim HJ, Rhee CK. Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. Respir Med. 2023;218:107410. https://doi.org/10.1016/j.rmed.2023.107410 . Teixeira MF, Rodrigues JC, Leone C, Adde FV. Acute bronchodilator responsiveness to tiotropium in postinfectious bronchiolitis obliterans in children. Chest. 2013;144(3):974–80. (PMID: 10.1378/chest.12-228023558666) Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346: e7586. (PMID: 10.1136/bmj.e7586233038843541470) The design and analysis of clinical experiments. Fleiss JL. Chichester: Wiley; 1986. p. 263–89. |
| فهرسة مساهمة: | Keywords: Bronchiolitis obliterans; Obstructive lung function; Tiotropium |
| المشرفين على المادة: | XX112XZP0J (Tiotropium Bromide) 0 (Bronchodilator Agents) |
| تواريخ الأحداث: | Date Created: 20240406 Date Completed: 20240408 Latest Revision: 20240425 |
| رمز التحديث: | 20240426 |
| DOI: | 10.1186/s13063-024-08051-7 |
| PMID: | 38582877 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1745-6215 |
|---|---|
| DOI: | 10.1186/s13063-024-08051-7 |